NASDAQ$BVS
Bioventus Inc - A · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Announced fourth quarter and full year financial results, demonstrating sales growth and improved profitability.
Bioventus reported a 7.6% increase in worldwide revenue for the fourth quarter, driven by strong organic growth in Pain Treatments and Surgical Solutions. The company's net loss decreased compared to the prior year, and adjusted EBITDA improved due to revenue growth and cost management. Full-year revenue remained consistent with the previous year, with growth in Surgical Solutions.
- Accelerated fourth quarter sales growth to 7.6%, with organic growth of 14.3%.
- Rob Claypoole was appointed as President and Chief Executive Officer.
- Net loss from continuing operations improved to $7.7 million compared to $35.4 million in the prior-year period.
- Adjusted EBITDA from continuing operations increased by 28.1% to $22.0 million.
Headline financials
Revenue & EPS history
Bioventus · Revenue · Quarterly
$135M
Forward guidance
Bioventus introduced its financial guidance for full-year 2024.
Tailwinds
- Net sales of $520 million to $535 million
- Adjusted EBITDA of $89 million to $94 million
- Non-GAAP EPS of $0.12 to $0.20
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+2.1%
Avg return
Earnings day
+5.6%
Avg return
5 days after
+13.1%
Avg return
30 days after
62%
13 / 21 earnings
Positive
+26.0%
Q1 2024
Best reaction
-39.9%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.2% | -4.6% | -15.4% | |
| Q4 2025 | +7.4% | +4.6% | +5.9% | |
| Q3 2025 | +15.1% | +13.6% | +16.2% | |
| Q1 2025 | -12.0% | -5.0% | -7.4% | |
| Q4 2024 | +23.3% | +9.7% | -13.6% | |
| Q3 2024 | -17.7% | -13.8% | -15.1% | |
| Q2 2024 | +19.2% | +21.2% | +54.3% | |
| Q1 2024 | +26.0% | +35.0% | +70.0% | |
| Q4 2023 | -0.4% | +2.6% | -9.4% | |
| Q3 2023 | +6.0% | -2.1% | +42.1% | |
| Q2 2023 | +20.3% | +32.9% | -2.6% | |
| Q1 2023 | +6.5% | +58.5% | +195.9% | |
| Q4 2022 | -6.6% | +2.5% | -16.5% | |
| Q3 2022 | -39.9% | -42.7% | -18.9% | |
| Q2 2022 | +4.8% | +3.9% | -6.4% | |
| Q1 2022 | -9.1% | +4.5% | +12.5% | |
| Q4 2021 | +0.8% | -3.0% | -4.0% | |
| Q3 2021 | -0.5% | -4.5% | -18.7% | |
| Q2 2021 | +1.7% | +0.3% | -0.7% | |
| Q1 2021 | +1.0% | +3.3% | +17.0% | |
| Q4 2020 | -4.8% | -0.4% | -9.1% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro